Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 5, 2005, Pages 487-490

  Walker, Paul R ^a   Khuder, Sadik A ^a   Quan Jr , Walter D Y ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Cimetidine; Famotidine; Interleukin 2; Kidney cancer; Lymphokine activated killer cells; Ranitidine

Indexed keywords

ANTIHISTAMINIC AGENT; CIMETIDINE; FAMOTIDINE; INTERLEUKIN 2; RANITIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; HUMAN; KIDNEY CANCER; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; CIMETIDINE; FAMOTIDINE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; RANITIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 27744582641     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.487     Document Type: Article

References (35)

1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 therapy in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S11.
2. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907.
3. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275.
4. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358.
5. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997;12:5.
6. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high-dose interleukin-2. Cancer Res 1990;50:1686.
7. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561.
8. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60.
9. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451.
10. Voss SD, Weil-Hillman G, Hank JA, et al. The clinical immunobiology of interleukin-2: Potential modified uses for improved cancer treatment. Bull NY Acad Med 1989;65:93.
11. Hank JA, Weil-Hillman G, et al. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 1990;31:53.
12. Hellstrand K, Brune M, Naredi P, et al. Histamine: A novel approach to cancer immunotherapy. Cancer Invest 2000;18:347.
13. Hellstrand K, Asea A, Dahlgren C, et al. Histaminergic regulation of NK-cells: Role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994;153:4940.
14. Hansson M, Hermodsson S, Brune M, et al. Histamine protects T-cells and NK cells against oxidative stress. J Interferon Cytokine Res 1999;19:1135.
15. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125.
16. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
17. Gaynor ER, Weiss GR, Margolin KA, et al. Phase I study of high-dose continuous infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 1990;82:1397.
18. Quan W, Jr, Brick W, Vinogradov M, et al. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. Cancer Biother Radiopharm 2004;19:350.
19. Kradin RL, Lazarus DS, Dubinett SM, et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;1:577.
20. Quan W, Jr, Ramirez M, Taylor C, et al. High-dose continuous infusion plus puise interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm 2005;20:36.
21. Shulman KL, Stadler WM, Vogelzang NJ. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal carcinoma: The University of Chicago experience. Urology 1996;47:194.
22. Quan W, Jr, Quan FM: Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2. Cancer Biother Radiopharm 2003;18:535.
23. West WH, Tauer KW, Yannelli JR, et al. Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma. Mol Biother 1989;1:268.
24. Thompson JA, Shulman KL, Benyunes MC, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992;10:960.
25. Clark JW, Smith JW II, Steis RG, et al. Interleukin-2 and lymphokine-activated killer-cell therapy: Analysis of a bolus interleukin-2 and a continuous infusion interleukin-2 regimen. Cancer Res 1990;50:7343.
26. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898.
27. Kikuchi Y, Oomori K, Kizawa I, et al. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma. Japn J Clin Oncol 1985;15:377.
28. Flodgren P, Sjogren HO: Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immun Immunother 1985;19:28.
29. Allen JI, Syropoulos HJ, Grant B, et al. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med 1987;109:396.
30. Tsunoda T, Tanimura H, Yamaue H, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1992;14:75.
31. Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002;41:362.
32. Quan W, Jr, Ramirez M, Taylor WC, et al. Continuous infusion plus pulse interleukin-2 and famotidine in melanoma. Cancer Biother Radiopharm 2004;19:770.
33. Evangelista-Dean M, Quan W, Jr, Khan N. Continuous infusion interleukin-2 and antihistamines in melanoma: A retrospective review showing activity of this combination. Cancer Biother Radiopharm 2004;19:757.
34. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother Radiopharm 1994;9:183.
35. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.